US · IPHA
Innate Pharma S.A.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Marseille 13009
- Website
- innate-pharma.com
Price · as of 2024-12-31
$1.44
Market cap 160.74M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $47.40 | +3,191.67% |
| Intrinsic Value(DCF) | $0.85 | -40.97% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $45.80 | +3,080.56% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $0.00 | $14.50 | |||
| 2011 | $0.00 | $0.00 | |||
| 2012 | $0.20 | $0.30 | |||
| 2013 | $0.80 | $0.00 | |||
| 2014 | $0.00 | $37.00 | |||
| 2015 | $0.90 | $0.00 | |||
| 2016 | $3.20 | $58.30 | |||
| 2017 | $0.00 | $33.20 | |||
| 2018 | $3.60 | $8.90 | |||
| 2019 | $7.08 | $80.30 | $548.37 | $2.00 | $1.80 |
| 2020 | $4.57 | $56.25 | $149.05 | $0.00 | $0.00 |
| 2021 | $3.08 | $36.14 | $0.69 | $0.00 | $55.10 |
| 2022 | $2.94 | $68.38 | $8.97 | $0.00 | $0.00 |
| 2023 | $2.70 | $29.51 | $4.98 | $0.20 | $0.20 |
| 2024 | $2.13 | $40.53 | $0.00 | $0.00 | $45.80 |
AI valuation
Our deep-learning model estimates Innate Pharma S.A.'s (IPHA) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $47.40
- Current price
- $1.44
- AI upside
- +3,191.67%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$0.85
-40.97% upside
Graham-Dodd
—
— upside
Graham Formula
$45.80
+3,080.56% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| IPHA | Innate Pharma S.A. | $1.44 | 160.74M | +2,715% | -41% | — | +3,081% | -2.98 | 16.70 | 11.69 | -2.08 | -0.52 | 16.70 | 100.00% | -408.64% | -391.97% | -162.91% | 247.94% | -34.57% | 3.51 | -91.12 | 2.60 | 2.50 | 0.75 | 57778.00% | -7568.00% | -7913.00% | -4.94% | -0.21 | 35.03% | 0.00% | 0.00% | 3.18% | -1.90 | -13.41 | 7.74 | -4.85 |
| APLT | Applied Therapeutics, Inc… | $0.10 | 14.86M | +30,191% | +123% | — | +60,988% | -0.76 | 1.40 | 175.54 | -0.03 | — | 1.40 | 100.00% | -22922.86% | -23214.07% | -529.97% | 242.94% | -149.27% | 0.05 | — | 3.06 | 2.91 | 0.74 | -4648.00% | -9545.00% | 5280.00% | -105.55% | -3.09 | 196.37% | 0.00% | 0.00% | 34.41% | -0.03 | -0.04 | 7.18 | -10.84 |
| CGEN | Compugen Ltd. | $1.81 | 169.3M | +2,407% | -50% | — | -30% | -10.44 | 2.71 | 5.33 | -3.35 | — | 2.71 | 71.54% | -53.44% | -51.07% | -23.63% | 101.98% | -12.04% | 0.05 | -437.97 | 5.26 | 5.14 | 1.06 | -2381.00% | -1672.00% | -23724.00% | 33.30% | 2.46 | -338.90% | 0.00% | 0.00% | 1.87% | -3.24 | 0.98 | 1.73 | -3.76 |
| CRBP | Corbus Pharmaceuticals Ho… | $8.57 | 107.43M | — | — | — | — | -1.84 | 0.52 | — | 1.90 | — | 0.52 | 0.00% | — | — | -59.34% | 944.11% | -43.67% | 0.02 | -26.03 | 12.94 | 12.61 | 0.37 | -6431.00% | — | 1577.00% | -56.39% | -3.54 | 809.88% | 0.00% | 0.00% | 28.50% | 1.47 | 1.72 | — | -0.92 |
| CRDF | Cardiff Oncology, Inc. | $1.94 | 130.68M | +1,196% | -60% | — | +59% | -2.83 | 2.86 | 218.67 | -1.61 | — | 2.86 | -52.45% | -8256.32% | -7736.26% | -71.45% | 505.84% | -57.65% | 0.02 | — | 3.67 | 3.57 | 0.37 | -2737.00% | -1318.00% | 51.00% | -29.28% | -2.31 | 392.26% | 0.00% | 0.00% | 0.00% | -1.47 | -1.90 | 121.75 | -6.77 |
| ELTX | Elicio Therapeutics, Inc. | $12.99 | 224.19M | — | — | — | — | -1.86 | -8.51 | — | -2.08 | — | -8.51 | 0.00% | — | — | -170157.38% | -3590.26% | -187.61% | -2.30 | -98.87 | 1.80 | 1.53 | -0.17 | -3894.00% | — | 1342.00% | -38.59% | -3.22 | -2965.28% | 0.00% | 0.00% | 0.00% | -2.33 | -2.82 | — | -13.06 |
| MIST | Milestone Pharmaceuticals… | $1.71 | 145.64M | +1,960% | — | — | — | -2.76 | 8.71 | — | -2.63 | — | 8.71 | 0.00% | — | — | -277.55% | -10631.82% | -55.09% | 4.17 | 11.76 | 9.10 | 8.87 | -0.78 | -5180.00% | -10000.00% | -3794.00% | -25.23% | -3.55 | -7293.18% | 0.00% | 0.00% | 7.45% | -2.36 | -3.45 | — | -6.51 |
| MOLN | Molecular Partners AG | $5.02 | 187.84M | +527% | -29% | — | +690% | -2.52 | 0.96 | 27.41 | 0.21 | — | 0.96 | -855.81% | -1231.73% | -1087.38% | -33.98% | 1006.36% | -30.29% | 0.02 | -2448.68 | 14.31 | 13.88 | 1.19 | -1587.00% | -2938.00% | 26.00% | -44.02% | -5.49 | 985.88% | 0.00% | 0.00% | 0.00% | 0.18 | 0.18 | -2.17 | 2.51 |
| NVCT | Nuvectis Pharma, Inc. | $8.86 | 234.72M | — | — | — | — | -7.46 | 10.71 | — | -6.00 | -39.42 | 10.71 | 0.00% | — | — | -188.03% | 250.21% | -105.10% | 0.00 | — | 2.38 | 2.38 | 1.15 | 1892.00% | — | 3072.00% | -8.12% | -1.20 | 145.27% | 0.00% | 0.00% | 6.64% | -6.00 | -10.34 | — | 2.32 |
| RANI | Rani Therapeutics Holding… | $1.37 | 100M | — | -55% | — | — | -0.79 | 22.30 | 43.21 | -0.92 | — | 22.30 | 100.00% | -5186.19% | -2920.04% | -761.66% | 7052.12% | -119.69% | 14.91 | -10.59 | 1.50 | 1.41 | -0.51 | -2105.00% | — | -3183.00% | -80.51% | -1.78 | 4730.69% | 0.00% | 0.00% | 0.00% | -0.87 | -1.30 | 45.23 | -7.58 |
About Innate Pharma S.A.
Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; and IPH6101, a NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers. Its products in preclinical trials are IPH43, an anti-MICA/B antibody drug conjugate; Anti-Siglec-9, an antibody program; IPH65, a tetraspecific proprietary antibody; IPH25, a checkpoint inhibitor; and IPH62 and IPH64 programs. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. The company was incorporated in 1999 and is headquartered in Marseille, France.
- CEO
- Jonathan E. Dickinson
- Employees
- 181
- Beta
- 0.57
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($0.85 ÷ $1.44) − 1 = -40.97% (DCF, example).